BioWorld

Aug. 19, 2009

Ofatumumab Misses NHL Mark; Genmab Shares Take a Tumble

Shares in Genmab A/S dropped sharply Tuesday on news that its anti-CD20 antibody ofatumumab failed to demonstrate a significant objective response rate in non-Hodgkins lymphoma (NHL) patients who were refractory to other treatments. (BioWorld Today) Read More

Geron Slips on Latest Delay to ESC Trial in Spinal Cord Injury

Adamas Snags Navy Flu Drug Contract, Raises $40M Series D

Crucell Gets Fat NIH Contract: Up to $69M for Bird-Flu Work

Corrections & Clarifications

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors

BioWorld Science

Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...